Xiaowei Wu

2.8k total citations
79 papers, 1.9k citations indexed

About

Xiaowei Wu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xiaowei Wu has authored 79 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 21 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Xiaowei Wu's work include RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (12 papers) and Ubiquitin and proteasome pathways (10 papers). Xiaowei Wu is often cited by papers focused on RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (12 papers) and Ubiquitin and proteasome pathways (10 papers). Xiaowei Wu collaborates with scholars based in China, United States and Singapore. Xiaowei Wu's co-authors include Zhihua Liu, Qingyu Luo, Pengfei Zhao, Wan Chang, Ziyi Fu, Yabing Nan, Hui Xie, Yangyang Cui, Yue Huang and Cong Li and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Xiaowei Wu

75 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaowei Wu China 27 1.3k 547 263 180 171 79 1.9k
Hao Peng China 30 1.2k 0.9× 443 0.8× 273 1.0× 155 0.9× 137 0.8× 126 2.7k
Lei Yuan China 26 1.3k 1.0× 556 1.0× 364 1.4× 109 0.6× 86 0.5× 102 2.2k
Jianhong Lu China 29 1.4k 1.1× 940 1.7× 520 2.0× 255 1.4× 155 0.9× 77 2.5k
Shih Sheng Jiang Taiwan 32 1.5k 1.2× 565 1.0× 449 1.7× 116 0.6× 86 0.5× 91 2.5k
Lanlan Wei China 23 708 0.6× 359 0.7× 292 1.1× 248 1.4× 91 0.5× 90 1.5k
Kai Xu China 31 1.7k 1.3× 626 1.1× 439 1.7× 191 1.1× 83 0.5× 112 2.8k
Talya L. Dayton United States 17 1.1k 0.9× 622 1.1× 460 1.7× 118 0.7× 56 0.3× 28 1.9k
Jian Gao China 26 973 0.8× 273 0.5× 314 1.2× 188 1.0× 49 0.3× 97 1.7k
Dan Guo China 26 1.2k 0.9× 811 1.5× 202 0.8× 116 0.6× 73 0.4× 95 1.9k
Lurong Zhang China 25 1.3k 1.1× 246 0.4× 281 1.1× 105 0.6× 77 0.5× 66 2.2k

Countries citing papers authored by Xiaowei Wu

Since Specialization
Citations

This map shows the geographic impact of Xiaowei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaowei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaowei Wu more than expected).

Fields of papers citing papers by Xiaowei Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaowei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaowei Wu. The network helps show where Xiaowei Wu may publish in the future.

Co-authorship network of co-authors of Xiaowei Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaowei Wu. A scholar is included among the top collaborators of Xiaowei Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaowei Wu. Xiaowei Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Du, Wei, Xiaowei Wu, Qingfeng Li, et al.. (2025). Integrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD. Discover Oncology. 16(1). 43–43. 2 indexed citations
2.
Nan, Yabing, Qingyu Luo, Xiaowei Wu, et al.. (2023). m6A demethylase FTO stabilizes LINK-A to exert oncogenic roles via MCM3-mediated cell-cycle progression and HIF-1α activation. Cell Reports. 42(10). 113273–113273. 15 indexed citations
3.
Zhao, Pengfei, Qingyu Luo, Xiaowei Wu, et al.. (2023). RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-κB activation and ovarian cancer progression. Oncogene. 43(6). 420–433. 9 indexed citations
4.
5.
Nan, Yabing, Qingyu Luo, Xiaowei Wu, et al.. (2022). HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity. Molecular Therapy. 31(2). 552–568. 23 indexed citations
6.
Nan, Yabing, Qingyu Luo, Xiaowei Wu, et al.. (2022). DLGAP1-AS2–Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma. Cancer Research. 82(16). 2887–2903. 19 indexed citations
7.
Chang, Wan, Qingyu Luo, Xiaowei Wu, et al.. (2022). OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis. Cell Reports. 41(4). 111561–111561. 28 indexed citations
8.
Zhang, Jing, Kui Ma, Xiangyu Wang, et al.. (2021). Desmoglein 2 (DSG2) Is A Receptor of Human Adenovirus Type 55 Causing Adult Severe Community-Acquired Pneumonia. Virologica Sinica. 36(6). 1400–1410. 8 indexed citations
9.
Luo, Qingyu, Xiaowei Wu, Pengfei Zhao, et al.. (2021). OTUD1 Activates Caspase‐Independent and Caspase‐Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. Advanced Science. 8(8). 2002874–2002874. 55 indexed citations
10.
Wu, Xiaowei, et al.. (2021). USP12 promotes breast cancer angiogenesis by maintaining midkine stability. Cell Death and Disease. 12(11). 1074–1074. 20 indexed citations
11.
Luo, Qingyu, Xiaowei Wu, & Zhihua Liu. (2020). Remodeling of the ARID1A tumor suppressor. Cancer Letters. 491. 1–10. 9 indexed citations
12.
Wu, Xiaowei, Qingyu Luo, & Zhihua Liu. (2020). Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death and Disease. 11(7). 556–556. 59 indexed citations
13.
Luo, Qingyu, Xiaowei Wu, Yabing Nan, et al.. (2020). TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Reports. 30(1). 98–111.e5. 40 indexed citations
14.
Luo, Qingyu, Xiaowei Wu, Wan Chang, et al.. (2019). ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. Cell Death and Differentiation. 27(6). 1981–1997. 35 indexed citations
15.
Wu, Xiaowei, Qingyu Luo, Pengfei Zhao, et al.. (2019). JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death and Differentiation. 27(1). 55–70. 54 indexed citations
16.
Zhang, Yiping, Furong Huang, Qingyu Luo, et al.. (2018). Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer. OncoTargets and Therapy. Volume 11. 8751–8759. 17 indexed citations
17.
Wu, Xiaowei, et al.. (2017). lncRNA expression character associated with ischemic reperfusion injury. Molecular Medicine Reports. 16(4). 3745–3752. 9 indexed citations
18.
Zhang, Minjie, Xiaowei Wu, Yingxiu Xu, et al.. (2017). The cystathionine β-synthase/hydrogen sulfide pathway contributes to microglia-mediated neuroinflammation following cerebral ischemia. Brain Behavior and Immunity. 66. 332–346. 73 indexed citations
19.
Shu, Tong, Yi Li, Xiaowei Wu, Bin Li, & Zhihua Liu. (2017). Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Cancer Letters. 411. 65–73. 19 indexed citations
20.
Fu, Ziyi, Chenbo Ji, Ping‐qing Gu, et al.. (2015). Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. Biomedicine & Pharmacotherapy. 72. 83–90. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hao Peng Breakdown of academic impact, for papers by Lei Yuan Breakdown of academic impact, for papers by Jianhong Lu Breakdown of academic impact, for papers by Shih Sheng Jiang Breakdown of academic impact, for papers by Lanlan Wei Breakdown of academic impact, for papers by Kai Xu Breakdown of academic impact, for papers by Talya L. Dayton Breakdown of academic impact, for papers by Jian Gao Breakdown of academic impact, for papers by Dan Guo Breakdown of academic impact, for papers by Lurong Zhang
Rankless by CCL
2026